PL3811967T3 - Wytwarzanie biologicznie aktywnych kompleksów - Google Patents
Wytwarzanie biologicznie aktywnych kompleksówInfo
- Publication number
- PL3811967T3 PL3811967T3 PL20208669.0T PL20208669T PL3811967T3 PL 3811967 T3 PL3811967 T3 PL 3811967T3 PL 20208669 T PL20208669 T PL 20208669T PL 3811967 T3 PL3811967 T3 PL 3811967T3
- Authority
- PL
- Poland
- Prior art keywords
- preparation
- biologically active
- active complexes
- complexes
- biologically
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Analytical Chemistry (AREA)
- Water Supply & Treatment (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Enzymes And Modification Thereof (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Inorganic Chemistry (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1707715.7A GB201707715D0 (en) | 2017-05-14 | 2017-05-14 | Preperation of biologically active complexes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3811967T3 true PL3811967T3 (pl) | 2024-03-18 |
Family
ID=59201543
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL20208669.0T PL3811967T3 (pl) | 2017-05-14 | 2018-05-14 | Wytwarzanie biologicznie aktywnych kompleksów |
| PL18729327T PL3618848T3 (pl) | 2017-05-14 | 2018-05-14 | Biologicznie aktywne kompleksy i ich zastosowania terapeutyczne |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL18729327T PL3618848T3 (pl) | 2017-05-14 | 2018-05-14 | Biologicznie aktywne kompleksy i ich zastosowania terapeutyczne |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US20200140481A1 (https=) |
| EP (2) | EP3618848B1 (https=) |
| JP (2) | JP7672122B2 (https=) |
| KR (2) | KR20260021814A (https=) |
| CN (2) | CN110650746B (https=) |
| AU (1) | AU2018269304B2 (https=) |
| CA (1) | CA3063285A1 (https=) |
| DK (2) | DK3618848T3 (https=) |
| ES (2) | ES2973290T3 (https=) |
| FI (1) | FI3811967T3 (https=) |
| GB (1) | GB201707715D0 (https=) |
| PL (2) | PL3811967T3 (https=) |
| WO (1) | WO2018210759A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201621752D0 (en) * | 2016-12-20 | 2017-02-01 | Hamlet Pharma Ab | Therapeutically active complexes |
| GB201707715D0 (en) * | 2017-05-14 | 2017-06-28 | Hamlet Pharma Ab | Preperation of biologically active complexes |
| GB2574845A (en) * | 2018-06-20 | 2019-12-25 | Hamlet Pharma Ab | Therapeutically active complexes |
| WO2019243547A1 (en) * | 2018-06-20 | 2019-12-26 | Hamlet Pharma Ab | Therapeutically active complexes |
| US20220323391A1 (en) * | 2019-08-20 | 2022-10-13 | Hamlet Pharma Ab | Combination of a chemotherapeutic agent and alpha-lactoglubulin-oleic acid complex for cancer therapy |
| GB202015836D0 (en) | 2020-10-06 | 2020-11-18 | Hamlet Pharma Ab | Compositions |
| AU2023357946A1 (en) | 2022-10-03 | 2025-04-24 | Linnane Pharma Ab | A complex comprising a alpha-lactalbumin and a fatty acid or lipid for use in the treatment or prevention of cancer |
| GB202303177D0 (en) | 2023-03-03 | 2023-04-19 | Linnane Pharma Ab | Method of predicting response to treatment |
| WO2025186107A1 (en) | 2024-03-04 | 2025-09-12 | Linnane Pharma Ab | Therapy |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2537273A1 (en) * | 2003-09-05 | 2005-03-17 | Gtc Biotherapeutics, Inc. | Method for the production of fusion proteins in transgenic mammal milk |
| DK2385954T3 (da) | 2009-01-09 | 2013-06-17 | Hamlet Pharma Ab | Kompleks og fremstillingsproces |
| WO2010131237A1 (en) | 2009-05-13 | 2010-11-18 | Agriculture And Food Development Authority (Teagasc) | A process for producing a biologically active globular protein complex |
| GB0908279D0 (en) | 2009-05-14 | 2009-06-24 | Enovate Systems Ltd | Subsea winch |
| DK2643010T3 (en) | 2010-11-24 | 2017-02-27 | Hamlet Pharma Ab | BIOLOGICAL ACTIVE COMPLEX AND ITS PREPARATION |
| EP3295953B1 (en) * | 2012-08-09 | 2020-10-21 | HAMLET Pharma AB | Milk protein - fatty acid complex |
| GB201621752D0 (en) * | 2016-12-20 | 2017-02-01 | Hamlet Pharma Ab | Therapeutically active complexes |
| GB201707715D0 (en) | 2017-05-14 | 2017-06-28 | Hamlet Pharma Ab | Preperation of biologically active complexes |
-
2017
- 2017-05-14 GB GBGB1707715.7A patent/GB201707715D0/en not_active Ceased
-
2018
- 2018-05-14 DK DK18729327.9T patent/DK3618848T3/da active
- 2018-05-14 ES ES20208669T patent/ES2973290T3/es active Active
- 2018-05-14 CN CN201880032057.6A patent/CN110650746B/zh active Active
- 2018-05-14 WO PCT/EP2018/062396 patent/WO2018210759A1/en not_active Ceased
- 2018-05-14 KR KR1020267002686A patent/KR20260021814A/ko active Pending
- 2018-05-14 DK DK20208669.0T patent/DK3811967T5/da active
- 2018-05-14 CA CA3063285A patent/CA3063285A1/en active Pending
- 2018-05-14 JP JP2019563219A patent/JP7672122B2/ja active Active
- 2018-05-14 PL PL20208669.0T patent/PL3811967T3/pl unknown
- 2018-05-14 US US16/612,272 patent/US20200140481A1/en not_active Abandoned
- 2018-05-14 AU AU2018269304A patent/AU2018269304B2/en active Active
- 2018-05-14 KR KR1020197037015A patent/KR20200015557A/ko not_active Ceased
- 2018-05-14 EP EP18729327.9A patent/EP3618848B1/en active Active
- 2018-05-14 EP EP20208669.0A patent/EP3811967B1/en active Active
- 2018-05-14 CN CN202411849059.8A patent/CN119700935A/zh active Pending
- 2018-05-14 ES ES18729327T patent/ES2861252T3/es active Active
- 2018-05-14 FI FIEP20208669.0T patent/FI3811967T3/fi active
- 2018-05-14 PL PL18729327T patent/PL3618848T3/pl unknown
-
2021
- 2021-01-12 US US17/146,588 patent/US12331073B2/en active Active
-
2023
- 2023-03-15 JP JP2023040807A patent/JP7705160B2/ja active Active
-
2025
- 2025-05-12 US US19/205,790 patent/US20260085088A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2020519673A (ja) | 2020-07-02 |
| CN110650746A (zh) | 2020-01-03 |
| JP2023075290A (ja) | 2023-05-30 |
| AU2018269304B2 (en) | 2025-02-27 |
| EP3811967A1 (en) | 2021-04-28 |
| CN119700935A (zh) | 2025-03-28 |
| DK3618848T3 (da) | 2021-03-01 |
| EP3618848A1 (en) | 2020-03-11 |
| KR20260021814A (ko) | 2026-02-13 |
| US20200140481A1 (en) | 2020-05-07 |
| WO2018210759A1 (en) | 2018-11-22 |
| ES2973290T3 (es) | 2024-06-19 |
| GB201707715D0 (en) | 2017-06-28 |
| EP3618848B1 (en) | 2020-11-25 |
| CN110650746B (zh) | 2024-12-31 |
| US12331073B2 (en) | 2025-06-17 |
| US20260085088A1 (en) | 2026-03-26 |
| US20210130394A1 (en) | 2021-05-06 |
| JP7705160B2 (ja) | 2025-07-09 |
| DK3811967T5 (da) | 2024-08-19 |
| DK3811967T3 (da) | 2024-01-08 |
| PL3618848T3 (pl) | 2021-06-14 |
| JP7672122B2 (ja) | 2025-05-07 |
| FI3811967T3 (fi) | 2023-12-28 |
| ES2861252T3 (es) | 2021-10-06 |
| EP3811967B1 (en) | 2023-12-20 |
| AU2018269304A1 (en) | 2019-11-21 |
| CA3063285A1 (en) | 2018-11-22 |
| KR20200015557A (ko) | 2020-02-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3811967T3 (pl) | Wytwarzanie biologicznie aktywnych kompleksów | |
| IL275046A (en) | History Phenylamidine kills microorganisms | |
| ZA201805747B (en) | Biologically active cannabidiol analogs | |
| EP3722497A4 (en) | FABRIC TREATMENT COMPOSITION | |
| AP2017009773A0 (en) | Encapsulation of hydrophobic biologically active compounds | |
| IL253803A0 (en) | A preparation for the treatment of hypothyroidism | |
| IL269061A (en) | A pharmaceutical preparation containing Selexifag | |
| IL254398A0 (en) | Antimicrobial compounds and methods for their preparation and use | |
| GB201501793D0 (en) | Encapsulation of high potency active agents | |
| GB201709141D0 (en) | Pharmaceutical formulation | |
| GB201813986D0 (en) | Coffins | |
| SG11201605868XA (en) | Pharmaceutical composition for cancer treatment and pharmaceutical preparation for cancer treatment containing same composition as active ingredient | |
| IL260766B (en) | Continuous production of complexes containing active pharmaceutical ingredients | |
| IL268514A (en) | Medical bacteriophage preparations | |
| IL272857A (en) | Cofanalisib formulations | |
| GB201621752D0 (en) | Therapeutically active complexes | |
| IL261891A (en) | Active retinal implant | |
| HUE059735T2 (hu) | Stabil, peszticid hatású piridazinpirazolamid-készítmény | |
| GB201909518D0 (en) | 4-N-Butylresorcinol preparations | |
| IL256486B1 (en) | Formulations to improve the effectiveness of hydrophobic drugs | |
| SI3381457T1 (sl) | Fiziološka aktivna sestava, ki vsebuje N-acetilglukozamin za zdravljenje bolečin v hrbtu | |
| PT3471702T (pt) | Formulação termoestável de substâncias biologicamente ativas | |
| AU201711233S (en) | Mobile patient bed | |
| ZA201908255B (en) | Treatment of oral candidiasis | |
| ZA201805215B (en) | Preparation for nasal-nasopharyngeal treatment |